PEOPLE - Metasyn adds four executives to senior management team:
This article was originally published in Clinica
Executive Summary
Metasyn, a US imaging agent company, has recently added four executives to its senior management team. Dr Stanley Crooke, founder, chairman and CEO of Isis Pharmaceuticals, has joined Metasyn's board of directors, and is named chairman of its scientific advisory board. Dr James Smith becomes executive vice-president of development. He was formerly senior director of radiopharmaceutical R&D with DuPont Merck Pharmaceutical. Dr Kent Yucel is named senior vice-president and chief medical officer. Prior to this he was chief of vascular and interventional radiology and director of MRI at Boston University Medical Centre. Dr Stephen Knight is appointed vice-president of strategic planning and corporate development. He was previously a senior manager in the healthcare practice Arthur D Little.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.